News

Morningstar3mon
Caris Life Sciences to Highlight Research at 2025 SGO Annual Meeting on Women's Cancer - Morningstar
"Caris and our POA collaborators are proud to present five studies at this year's SGO Annual Meeting highlighting the critical role of molecular profiling and biomarkers in personalizing treatment ...
KRON4 News3mon
Akeso's Cadonilimab Combined with Concurrent Chemoradiotherapy Demonstrates Promising Efficacy in Locally Advanced Cervical Cancer: Data Published at the 2025 SGO Annual Meeting
HONG KONG, March 20, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) presented promising phase III safety run-in results from the COMPASSION-18/AK104-305 study, at the 2025 Annual Meeting of the Society ...
Business Insider2y
Aadi Bioscience Presents Clinical Data from PRECISION 1 and AMPECT Trials at the Society of Gynecological Oncology (SGO) Annual Meeting on Women's Cancer - Markets Insider
LOS ANGELES, March 26, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developi ...
Nasdaq3mon
Sutro Biopharma Presents Positive Late-Breaking Data on Luveltamab Tazevibulin for Platinum Resistant Ovarian Cancer at SGO Annual Meeting - Nasdaq
The SGO Annual Meeting will take place from March 14-17, 2025 in Seattle, Washington. In this study, ...
Medical Xpress2y
Clinical study: Treatment improves outcomes for women with locally advanced vulvar cancer - Medical Xpress
These findings were presented during the Plenary Session at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer.
Yahoo Finance3mon
Caris Life Sciences to Highlight Research at 2025 SGO Annual Meeting on Women's Cancer - Yahoo Finance
Caris Life Sciences Logo (PRNewsfoto/Caris Life Sciences) "Caris and our POA collaborators are proud to present five studies at this year's SGO Annual Meeting highlighting the critical role of ...
Yahoo Finance3mon
Akeso's Cadonilimab Combined with Concurrent Chemoradiotherapy Demonstrates Promising Efficacy in Locally Advanced Cervical Cancer: Data Published at the 2025 SGO Annual Meeting
Akeso Inc. (9926.HK) presented promising phase III safety run-in results from the COMPASSION-18/AK104-305 study, at the 2025 Annual Meeting of the Society of Gynecologic Oncology (SGO). The study ...